Vor Biopharma (VOR) 10-Q 6 May 21 2021 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2021	Apr. 30, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Current Fiscal Year End Date	--12-31
Entity Registrant Name	VOR BIOPHARMA INC.
Entity Central Index Key	0001817229
Entity File Number	001-39979
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	81-1591163
Entity Address, Address Line One	100 Cambridgepark Drive
Entity Address, Address Line Two	Suite 400
Entity Address, City or Town	Cambridge
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02140
City Area Code	617
Local Phone Number	655-6580
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		37,131,633
Entity Shell Company	false
Document Quarterly Report	true
Document Transition Report	false
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	VOR
Security Exchange Name	NASDAQ

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 262,567	$ 48,539
Prepaid expenses	3,606	467
Other current assets	92	100
Total current assets	266,265	49,106
Restricted cash	1,559	1,559
Property and equipment, net	5,737	4,728
Operating lease right-of-use assets	16,796	17,117
Other assets	2,582	3,398
Total assets	292,939	75,908
Current liabilities:
Accounts payable	2,406	2,361
Accrued expenses	4,395	6,260
Operating lease liability	1,155	863
Other current liabilities	675	723
Total current liabilities	8,631	10,207
Long-term liabilities:
Operating lease liabilities—non-current	17,121	17,430
Total liabilities	25,752	27,637
Redeemable convertible preferred stock		107,336
Stockholders’ equity (deficit):
Preferred stock, $0.0001 par value; 10,000,000 and 0 shares authorized as of March 31, 2021 and December 31, 2020, respectively; 0 shares issued and outstanding as of March 31, 2021 and December 31, 2020
Common stock, $0.0001 par value; 400,000,000 and 420,000,000 shares authorized as of March 31, 2021 and December 31, 2020 respectively; 37,129,729 and 893,231 shares issued and 36,770,010 and 505,074 outstanding as of March 31, 2021 and December 31, 2020, respectively	4	1
Additional paid-in capital	342,130	2,158
Accumulated deficit	(74,947)	(61,224)
Total stockholders’ equity (deficit)	267,187	(59,065)
Total liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit)	$ 292,939	75,908
Series A-1 Redeemable Convertible Preferred Stock
Long-term liabilities:
Redeemable convertible preferred stock		2
Series A-2 Redeemable Convertible Preferred Stock
Long-term liabilities:
Redeemable convertible preferred stock		42,786
Series B Redeemable Convertible Preferred Stock
Long-term liabilities:
Redeemable convertible preferred stock		$ 64,548

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Redeemable convertible preferred stock, shares authorized		338,973,691
Redeemable convertible preferred stock, shares issued		251,714,086
Redeemable convertible preferred stock, shares outstanding		251,714,086
Redeemable convertible preferred stock, liquidation preference		$ 111,628
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	0
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	400,000,000	420,000,000
Common stock, shares issued	37,129,729	893,231
Common stock, shares outstanding	36,770,010	505,074
Series A-1 Redeemable Convertible Preferred Stock
Redeemable convertible preferred stock, par value	$ 0.0001	$ 0.0001
Redeemable convertible preferred stock, shares authorized	0	20,000,000
Redeemable convertible preferred stock, shares issued	0	20,000,000
Redeemable convertible preferred stock, shares outstanding	0	20,000,000
Redeemable convertible preferred stock, liquidation preference		$ 4,000
Series A-2 Redeemable Convertible Preferred Stock
Redeemable convertible preferred stock, par value	$ 0.0001	$ 0.0001
Redeemable convertible preferred stock, shares authorized	0	107,194,866
Redeemable convertible preferred stock, shares issued	0	107,194,866
Redeemable convertible preferred stock, shares outstanding	0	107,194,866
Redeemable convertible preferred stock, liquidation preference		$ 42,878
Series B Redeemable Convertible Preferred Stock
Redeemable convertible preferred stock, par value	$ 0.0001	$ 0.0001
Redeemable convertible preferred stock, shares authorized	0	211,778,825
Redeemable convertible preferred stock, shares issued	0	124,519,220
Redeemable convertible preferred stock, shares outstanding	0	124,519,220
Redeemable convertible preferred stock, liquidation preference		$ 64,750

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Operating expenses:
Research and development	$ 8,941	$ 6,171
General and administrative	4,789	1,707
Total operating expenses	13,730	7,878
Loss from operations	(13,730)	(7,878)
Other income:
Interest income	7	29
Total other income	7	29
Net loss and comprehensive loss	(13,723)	(7,849)
Cumulative dividends on redeemable convertible preferred stock	(1,228)	(715)
Net loss attributable to common stockholders	$ (14,951)	$ (8,564)
Net loss per share attributable to common stockholders, basic and diluted	$ (0.67)	$ (59.06)
Weighted-average common shares outstanding, basic and diluted	22,263,994	145,016

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Series A-1 Redeemable Convertible Preferred Stock	Series A-2 Redeemable Convertible Preferred Stock	Series B Redeemable Convertible Preferred Stock
Beginning Balance at Dec. 31, 2019	$ (17,429)		$ 458	$ (17,887)
Beginning Balance, Shares at Dec. 31, 2019		119,936
Beginning Balance at Dec. 31, 2019					$ 2	$ 25,067
Beginning Balance, Shares at Dec. 31, 2019					20,000,000	62,819,866
Issuance of redeemable convertible preferred stock						$ 17,719
Issuance of redeemable convertible preferred stock, Shares						44,375,000
Issuance of common stock upon exercise of stock options	43		43
Issuance of common stock upon exercise of stock options, Shares		31,384
Stock-based compensation expense	112		112
Net loss	(7,849)			(7,849)
Ending Balance at Mar. 31, 2020					$ 2	$ 42,786
Ending Balance, Shares at Mar. 31, 2020					20,000,000	107,194,866
Ending Balance at Mar. 31, 2020	(25,123)		613	(25,736)
Ending Balance, Shares at Mar. 31, 2020		151,320
Beginning Balance at Dec. 31, 2020	$ (59,065)	$ 1	2,158	(61,224)
Beginning Balance, Shares at Dec. 31, 2020	505,074	505,074
Beginning Balance at Dec. 31, 2020	$ 107,336				$ 2	$ 42,786	$ 64,548
Beginning Balance, Shares at Dec. 31, 2020	251,714,086				20,000,000	107,194,866	124,519,220
Issuance of redeemable convertible preferred stock							$ 45,375
Issuance of redeemable convertible preferred stock, Shares							87,259,605
Conversion of redeemable convertible preferred stock into common stock upon closing of initial public offering					$ (2)	$ (42,786)	$ (109,923)
Conversion of redeemable convertible preferred stock into common stock upon closing of initial public offering, Shares					(20,000,000)	(107,194,866)	(211,778,825)
Conversion of redeemable convertible preferred stock into common stock upon closing of initial public offering	$ 152,711	$ 2	152,709
Conversion of redeemable convertible preferred stock into common stock upon closing of initial public offering, Shares		24,924,501
Issuance of common shares upon closing of initial public offering, net of offering costs and underwriter fees of $17,132	186,308	$ 1	186,307
Issuance of common shares upon closing of initial public offering, net of offering costs and underwriter fees, Shares		11,302,219
Issuance of common stock upon exercise of stock options	$ 65		65
Issuance of common stock upon exercise of stock options, Shares	38,216	38,216
Stock-based compensation expense	$ 891		891
Net loss	(13,723)			(13,723)
Ending Balance, Shares at Mar. 31, 2021					0	0	0
Ending Balance at Mar. 31, 2021	$ 267,187	$ 4	$ 342,130	$ (74,947)
Ending Balance, Shares at Mar. 31, 2021	36,770,010	36,770,010

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical) $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)
Statement Of Stockholders Equity [Abstract]
Issuance of common shares upon closing of initial public offering, offering costs and underwriter fees	$ 17,132

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash flows from operating activities
Net loss	$ (13,723)	$ (7,849)
Adjustments to reconcile net loss to net cash used in operations:
Depreciation expense	311	66
Non-cash lease expense	322
Stock-based compensation	891	112
Changes in operating assets and liabilities:
Operating lease liability	(16)
Prepaid expenses and other current assets	(3,131)	(347)
Accounts payable and accrued expenses	(2,444)	1,933
Other assets	141
Net cash used in operating activities	(17,649)	(6,085)
Cash flow from investing activities
Purchases of property and equipment	(1,171)	(545)
Net cash used in investing activities	(1,171)	(545)
Cash flow from financing activities
Proceeds from issuance of redeemable convertible preferred stock	45,375	17,719
Proceeds from the issuance of common stock upon closing of initial public offering, net of underwriter fees	189,199
Payment of initial public offering costs	(1,744)
Proceeds from stock option exercises	18	43
Net cash provided by financing activities	232,848	17,762
Net increase in cash, cash equivalents and restricted cash	214,028	11,132
Cash, cash equivalents and restricted cash, beginning of period	50,098	8,025
Cash, cash equivalents and restricted cash, end of period	264,126	19,157
Supplemental disclosure of non-cash activities
Conversion of redeemable convertible preferred stock to common stock upon closing of the initial public offering	152,711
Purchases of property and equipment in accounts payable	149	$ 270
Deferred offering costs in accounts payable and accrued expenses	$ 471

Nature of the Business

Nature of the Business	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Nature of the Business	1. Nature of the Business Vor Biopharma Inc. (the “Company” or “Vor”) is a cell therapy company that combines a novel patient engineering approach with targeted therapies to provide a single company solution for patients suffering from hematological malignancies. The Company’s proprietary platform leverages its expertise in hematopoietic stem cell (“HSC”) biology, genome engineering and targeted therapy development to genetically modify HSCs to remove surface targets expressed by cancer cells. Vor is headquartered in Cambridge, Massachusetts. The Company was incorporated on December 30, 2015 as a wholly owned subsidiary of PureTech Health LLC. Initial Public Offering On February 9, 2021, the Company completed an initial public offering (“IPO”) of its common stock. At the closing of the IPO, the Company issued and sold 11,302,219 shares of its common stock, at a public offering price of $18.00 per share. The Company received net proceeds of approximately $186.3 million from the IPO, after deducting underwriters’ discounts and commissions and other offering expenses paid by the Company. Upon closing of the IPO, all shares of the Company’s Series A-1, A-2 and B redeemable convertible preferred stock then outstanding automatically converted into an aggregate of 24,924,501 shares of common stock. Upon conversion of the redeemable convertible preferred stock, the Company reclassified the carrying value of the redeemable convertible preferred stock to common stock and additional paid-in capital. In connection with the IPO, the Company filed an amended and restated certificate of incorporation that amended and restated the Company’s certificate of incorporation in its entirety to, among other things, authorize the Company to issue up to 400,000,000 shares of common stock, $0.0001 par value per share, and 10,000,000 shares of preferred stock, $0.0001 par value per share, all of which shares of preferred stock are undesignated. In addition, the Company’s board of directors may establish the rights and preferences of the preferred stock from time to time. Reverse Stock Split On January 29, 2021, the Company effected a 13.6-for-1 reverse stock split of the Company’s common stock. All shares, stock options, and per share information in the condensed consolidated financial statements were previously adjusted to reflect the reverse stock split. There was no change in the par value and authorized number of shares of the Company’s common stock. Risks and Uncertainties The Company is subject to a number of risks common to development stage companies in the biotechnology industry, including, but not limited to, risks of failure of preclinical studies and clinical trials, dependence on key personnel, protection of proprietary technology, reliance on third party organizations, risks of obtaining regulatory approval for any product candidate that it may develop, development by competitors of technological innovations, compliance with government regulations, the impact of the COVID-19 pandemic, and the need to obtain additional financing. The Company anticipates that it will continue to incur significant operating losses for the next several years as it continues to develop its product candidates. The Company believes that its existing cash and cash equivalents at March 31, 2021 will be sufficient to allow the Company to fund its current operations through at least a period of one year after the date the financial statements are issued.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). Use of Estimates The preparation of the consolidated financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amount of expenses during the reporting period. Actual results could differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies in developing the estimates and assumptions that are used in the preparation of the consolidated financial statements. Management must apply significant judgment in this process. Management’s estimation process often may yield a range of potentially reasonable estimates and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: estimating the fair value of the Company’s common stock (prior to the IPO); accrued expenses and research and development expenses. Unaudited Interim Financial Information The consolidated financial statements of the Company included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, the information furnished reflects all adjustments, all of which are of a normal and recurring nature, necessary for a fair presentation of the results for the reported interim periods. The results of operations for interim periods are not necessarily indicative of results to be expected for the full year or any other interim period. The accompanying condensed consolidated balance sheet as of December 31, 2020 has been derived from the Company’s audited consolidated financial statements for the year ended December 31, 2020. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to rules and regulations. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited annual consolidated financial statements and notes in the Company's Annual Report on Form 10-K for the year ended December 31, 2020 (the “2020 Annual Report”). During the three months ended March 31, 2021, there have been no changes to the Company’s significant accounting policies as described in the 2020 Annual Report. Recent Accounting Pronouncements In 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740)

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	3. Fair Value Measurements The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis: March 31, 2021 (in thousands) Level 1 Level 2 Level 3 Total Money market fund $ 41,043 $ — $ — $ 41,043 Total $ 41,043 $ — $ — $ 41,043 December 31, 2020 (in thousands) Level 1 Level 2 Level 3 Total Money market fund $ 41,036 $ — $ — $ 41,036 Total $ 41,036 $ — $ — $ 41,036 During the three months ended March 31, 2021 and year ended December 31, 2020, there were no transfers between levels. The fair value of the Company’s cash equivalents, consisting of a money market fund, is based on quoted market prices in active markets with no valuation adjustment.

Property and Equipment, Net

Property and Equipment, Net	3 Months Ended
	Mar. 31, 2021
Property Plant And Equipment [Abstract]
Property and Equipment, Net	4. Property and Equipment, Net Property and equipment, net consisted of the following: March 31, December 31, (in thousands) 2021 2020 Furniture and equipment $ 40 $ 40 Laboratory equipment 6,558 5,247 Computer equipment 176 167 Property and equipment, gross 6,774 5,454 Accumulated depreciation (1,037 ) (726 ) Property and equipment, net $ 5,737 $ 4,728 Depreciation expense for the three months ended March 31, 2021 and 2020 was approximately $0.3 million and $0.1 million, respectively.

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	3 Months Ended
	Mar. 31, 2021
Payables And Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	5. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following: March 31, December 31, (in thousands) 2021 2020 Accrued employee-related and other expenses $ 1,598 $ 2,727 Accrued research and development 1,669 1,924 Accrued professional fees 997 1,097 Accrued license and milestone fees 80 450 Accrued other 51 62 Total accrued expenses $ 4,395 $ 6,260

Equity

Equity	3 Months Ended
	Mar. 31, 2021
Equity [Abstract]
Equity	6. Equity Redeemable Convertible Preferred Stock Prior to the IPO, the Company had issued Series A-1 redeemable convertible preferred stock (“Series A-1”), Series A-2 redeemable convertible preferred stock (“Series A-2”) and Series B redeemable convertible preferred stock (“Series B” and collectively with the Series A-1 and Series A-2, “Redeemable Convertible Preferred Stock”). Series A-2 Redeemable Convertible Preferred Stock Closing In February 2019 and 2020, the Company issued and sold 88,750,000 and 44,375,000 shares of Series A-2, respectively, at a purchase price of $0.40 per share for total gross cash proceeds of $35.6 million. Series B Redeemable Convertible Preferred Stock Closing In June 2020 and January 2021, the Company issued and sold 124,519,220 and 87,259,605 shares of Series B, respectively, at a purchase price of $0.52 per share for total gross cash proceeds of $110.1 million. As of December 31, 2020, redeemable convertible preferred stock consisted of the following: (in thousands, except share amounts) Preferred Stock Authorized Preferred Stock Issued and Outstanding Carrying Value Liquidation Value Cumulative Undeclared Dividends Common Stock Issuable Upon Conversion Series A-1 redeemable convertible preferred stock 20,000,000 20,000,000 $ 2 $ 4,000 $ — 1,470,588 Series A-2 redeemable convertible preferred stock 107,194,866 107,194,866 42,786 42,878 5,073 7,881,965 Series B redeemable convertible preferred stock 211,778,825 124,519,220 64,548 64,750 2,625 9,155,810 Total 338,973,691 251,714,086 $ 107,336 $ 111,628 $ 7,698 18,508,363

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	7. Stock-Based Compensation Stock Incentive Plan In December 2015, the Company’s board of directors adopted and approved the 2015 Stock Incentive Plan (the “2015 Plan”). The 2015 Plan provided for the granting of incentive stock options, non-statutory stock options, restricted stock awards and other stock-based awards to eligible employees, officers, directors, consultants and advisors as determined by the Company’s board of directors. In February 2021, the Company’s board of directors adopted and the stockholders approved the 2021 Equity Incentive Plan (the “2021 Plan”). The 2021 Plan became effective on February 5, 2021, following which no further grants were or will be made under the 2015 Plan. The 2021 Plan provides for the grant of stock options, non-statutory stock options, restricted stock awards, restricted stock unit awards, stock appreciation rights, performance stock awards and other forms of stock compensation to our employees, consultants and directors. As of March 31, 2021, the Company had 2,693,301 shares available for future issuance under the 2021 Plan. Stock Options The Company’s stock options generally vest over 48 months with 25% vesting after one year followed by ratable monthly vesting over the remaining three years and have a contractual term of 10 years. The weighted-average assumptions used principally in determining the fair value of options granted were as follows: Three Months Ended March 31, 2021 2020 Fair value of common stock $ 22.51 $ 2.18 Expected term (in years) 6.0 5.9 Expected volatility 79.7 % 75.9 % Risk-free interest rate 0.7 % 0.7 % Dividend yield — — The following table summarizes the Company’s stock option activity for three months ended March 31, 2021: Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (in years) Aggregate Intrinsic Value (in thousands) Outstanding at January 1, 2021 5,084,679 $ 3.79 9.42 $ 32,086 Granted 394,934 $ 22.51 Exercised (38,216 ) $ 1.31 Outstanding at March 31, 2021 5,441,397 $ 5.16 9.24 $ 206,544 Exercisable at March 31, 2021 989,860 $ 1.80 8.85 $ 40,772 The aggregate intrinsic value of options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common stock for those stock options that had exercise prices lower than the fair value of the common stock as of the end of the period. The weighted-average grant-date fair value of stock options granted during the three months ended March 31, 2021 and 2020 was $15.27 and $1.42 per share, respectively. As March 31, 2021, total unrecognized compensation expense related to stock options was $13.9 million which is expected to be recognized over a weighted-average period of 3.11 years. As of March 31, 2021, options for 359,719 shares with a weighted average exercise price of $1.35 were exercised and unvested. The underlying proceeds from the unvested exercises of $0.7 million is recorded in other current liabilities on the consolidated balance sheet. Stock-Based Compensation Stock-based compensation expense was allocated as follows: Three Months Ended March 31, (in thousands) 2021 2020 Research and development $ 449 $ 47 General and administrative 442 65 Total stock-based compensation expense $ 891 $ 112

Leases

Leases	3 Months Ended
	Mar. 31, 2021
Leases [Abstract]
Leases	8. Leases Since December 31, 2020, there have been no material changes to the key terms of the Company’s lease agreements. For further information on terms and conditions of the Company’s existing leases, please see Note 10. Leases to the consolidated financial statements included in the 2020 Annual Report. The elements of lease expense were as follows: Three Months Ended March 31, (in thousands except weighted-average amounts) 2021 2020 Operating lease cost $ 747 $ — Short-term lease cost 52 153 Variable lease cost 122 48 Total lease cost $ 921 $ 201 Other Information Cash paid for amounts included in the measurement of lease liabilities Operating cash flows for operating leases $ 442 $ — Weighted-average remaining lease term (years) 9.33 — Weighted-average discount rate 9.36 % — Right-of-use lease assets and lease liabilities are reported in the Company’s consolidated balance sheets as follows: (in thousands) March 31, 2021 December 31, 2020 Assets Operating right-of-use assets $ 16,796 $ 17,117 Liabilities Operating lease liabilities, current $ 1,155 $ 863 Operating lease liabilities, non-current $ 17,121 $ 17,430 Total lease liabilities $ 18,276 $ 18,293

Significant Agreements

Significant Agreements	3 Months Ended
	Mar. 31, 2021
Significant Agreements [Abstract]
Significant Agreements	9. Significant Agreements Since December 31, 2020, there have been no material changes to the key terms of the Company’s license agreements. For further information on terms and conditions of the Company’s existing license agreements, please see Note 11. Significant Agreements to the consolidated financial statements included in the 2020 Annual Report.

Net Loss Per Share

Net Loss Per Share	3 Months Ended
	Mar. 31, 2021
Earnings Per Share [Abstract]
Net Loss Per Share	10. Net Loss Per Share The following table sets forth the computation of the Company’s basic and diluted net loss per share for the three months ended March 31, 2021 and 2020: Three Months Ended March 31, (in thousands, except share and per share amounts) 2021 2020 Numerator: Net loss $ (13,723 ) $ (7,849 ) Cumulative dividends on redeemable convertible preferred stock (1,228 ) (715 ) Net loss attributable to common stockholders $ (14,951 ) $ (8,564 ) Denominator: Weighted-average number of common shares outstanding, basic and diluted 22,263,994 145,016 Net loss per share attributable to common stockholders, basic and diluted $ (0.67 ) $ (59.06 ) As of March 31, 2021 and 2020, the Company’s potentially dilutive securities were redeemable convertible preferred stock and stock options. Based on the amounts outstanding at March 31, 2021 and 2020, the Company excluded the following potential common shares from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect: Three Months Ended March 31, 2021 2020 Series A-1 redeemable convertible preferred stock — 20,000,000 Series A-2 redeemable convertible preferred stock — 107,194,866 Options to purchase common stock 5,441,397 1,753,429

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”).
Use of Estimates	Use of Estimates The preparation of the consolidated financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amount of expenses during the reporting period. Actual results could differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies in developing the estimates and assumptions that are used in the preparation of the consolidated financial statements. Management must apply significant judgment in this process. Management’s estimation process often may yield a range of potentially reasonable estimates and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: estimating the fair value of the Company’s common stock (prior to the IPO); accrued expenses and research and development expenses.
Unaudited Interim Financial Information	Unaudited Interim Financial Information The consolidated financial statements of the Company included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, the information furnished reflects all adjustments, all of which are of a normal and recurring nature, necessary for a fair presentation of the results for the reported interim periods. The results of operations for interim periods are not necessarily indicative of results to be expected for the full year or any other interim period. The accompanying condensed consolidated balance sheet as of December 31, 2020 has been derived from the Company’s audited consolidated financial statements for the year ended December 31, 2020. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to rules and regulations. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited annual consolidated financial statements and notes in the Company's Annual Report on Form 10-K for the year ended December 31, 2020 (the “2020 Annual Report”). During the three months ended March 31, 2021, there have been no changes to the Company’s significant accounting policies as described in the 2020 Annual Report.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740)

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis: March 31, 2021 (in thousands) Level 1 Level 2 Level 3 Total Money market fund $ 41,043 $ — $ — $ 41,043 Total $ 41,043 $ — $ — $ 41,043 December 31, 2020 (in thousands) Level 1 Level 2 Level 3 Total Money market fund $ 41,036 $ — $ — $ 41,036 Total $ 41,036 $ — $ — $ 41,036

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	3 Months Ended
	Mar. 31, 2021
Property Plant And Equipment [Abstract]
Schedule of Property and Equipment, Net	Property and equipment, net consisted of the following: March 31, December 31, (in thousands) 2021 2020 Furniture and equipment $ 40 $ 40 Laboratory equipment 6,558 5,247 Computer equipment 176 167 Property and equipment, gross 6,774 5,454 Accumulated depreciation (1,037 ) (726 ) Property and equipment, net $ 5,737 $ 4,728

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	3 Months Ended
	Mar. 31, 2021
Payables And Accruals [Abstract]
Schedule of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consisted of the following: March 31, December 31, (in thousands) 2021 2020 Accrued employee-related and other expenses $ 1,598 $ 2,727 Accrued research and development 1,669 1,924 Accrued professional fees 997 1,097 Accrued license and milestone fees 80 450 Accrued other 51 62 Total accrued expenses $ 4,395 $ 6,260

Equity (Tables)

Equity (Tables)	3 Months Ended
	Mar. 31, 2021
Equity [Abstract]
Summary of Redeemable Convertible Preferred Stock	As of December 31, 2020, redeemable convertible preferred stock consisted of the following: (in thousands, except share amounts) Preferred Stock Authorized Preferred Stock Issued and Outstanding Carrying Value Liquidation Value Cumulative Undeclared Dividends Common Stock Issuable Upon Conversion Series A-1 redeemable convertible preferred stock 20,000,000 20,000,000 $ 2 $ 4,000 $ — 1,470,588 Series A-2 redeemable convertible preferred stock 107,194,866 107,194,866 42,786 42,878 5,073 7,881,965 Series B redeemable convertible preferred stock 211,778,825 124,519,220 64,548 64,750 2,625 9,155,810 Total 338,973,691 251,714,086 $ 107,336 $ 111,628 $ 7,698 18,508,363

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Weighted-Average Assumptions Used Principally in Determining Fair Value of Options Granted	The weighted-average assumptions used principally in determining the fair value of options granted were as follows: Three Months Ended March 31, 2021 2020 Fair value of common stock $ 22.51 $ 2.18 Expected term (in years) 6.0 5.9 Expected volatility 79.7 % 75.9 % Risk-free interest rate 0.7 % 0.7 % Dividend yield — —
Summary of Stock Option Activity	The following table summarizes the Company’s stock option activity for three months ended March 31, 2021: Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (in years) Aggregate Intrinsic Value (in thousands) Outstanding at January 1, 2021 5,084,679 $ 3.79 9.42 $ 32,086 Granted 394,934 $ 22.51 Exercised (38,216 ) $ 1.31 Outstanding at March 31, 2021 5,441,397 $ 5.16 9.24 $ 206,544 Exercisable at March 31, 2021 989,860 $ 1.80 8.85 $ 40,772
Summary of Stock-Based Compensation Expense	Stock-based compensation expense was allocated as follows: Three Months Ended March 31, (in thousands) 2021 2020 Research and development $ 449 $ 47 General and administrative 442 65 Total stock-based compensation expense $ 891 $ 112

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2021
Leases [Abstract]
Summary of Lease Expense	The elements of lease expense were as follows: Three Months Ended March 31, (in thousands except weighted-average amounts) 2021 2020 Operating lease cost $ 747 $ — Short-term lease cost 52 153 Variable lease cost 122 48 Total lease cost $ 921 $ 201 Other Information Cash paid for amounts included in the measurement of lease liabilities Operating cash flows for operating leases $ 442 $ — Weighted-average remaining lease term (years) 9.33 — Weighted-average discount rate 9.36 % —
Summary of Right-of-Use Assets and Lease Liabilities	Right-of-use lease assets and lease liabilities are reported in the Company’s consolidated balance sheets as follows: (in thousands) March 31, 2021 December 31, 2020 Assets Operating right-of-use assets $ 16,796 $ 17,117 Liabilities Operating lease liabilities, current $ 1,155 $ 863 Operating lease liabilities, non-current $ 17,121 $ 17,430 Total lease liabilities $ 18,276 $ 18,293

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2021
Earnings Per Share [Abstract]
Schedule of Computation of Basic and Diluted Net Loss Per Share	The following table sets forth the computation of the Company’s basic and diluted net loss per share for the three months ended March 31, 2021 and 2020: Three Months Ended March 31, (in thousands, except share and per share amounts) 2021 2020 Numerator: Net loss $ (13,723 ) $ (7,849 ) Cumulative dividends on redeemable convertible preferred stock (1,228 ) (715 ) Net loss attributable to common stockholders $ (14,951 ) $ (8,564 ) Denominator: Weighted-average number of common shares outstanding, basic and diluted 22,263,994 145,016 Net loss per share attributable to common stockholders, basic and diluted $ (0.67 ) $ (59.06 )
Potential Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share	As of March 31, 2021 and 2020, the Company’s potentially dilutive securities were redeemable convertible preferred stock and stock options. Based on the amounts outstanding at March 31, 2021 and 2020, the Company excluded the following potential common shares from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect: Three Months Ended March 31, 2021 2020 Series A-1 redeemable convertible preferred stock — 20,000,000 Series A-2 redeemable convertible preferred stock — 107,194,866 Options to purchase common stock 5,441,397 1,753,429

Nature of the Business - Additi

Nature of the Business - Additional Information (Details) $ / shares in Units, $ in Thousands	Feb. 09, 2021USD ($)$ / sharesshares	Jan. 29, 2021	Mar. 31, 2021USD ($)$ / sharesshares	Dec. 31, 2020$ / sharesshares
Nature Of Business [Line Items]
Incorporation date			Dec. 30, 2015
Net proceeds from issuance of IPO | $			$ 189,199
Common stock, shares authorized	400,000,000		400,000,000	420,000,000
Common stock, par value | $ / shares	$ 0.0001		$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000		10,000,000	0
Preferred stock, par value | $ / shares	$ 0.0001		$ 0.0001	$ 0.0001
Common Stock
Nature Of Business [Line Items]
Common stock shares issued and sold			11,302,219
Net proceeds from issuance of IPO | $	$ 186,300
Common stock shares issued for conversion of redeemable convertible preferred stock	24,924,501		24,924,501
Stockholders' equity, reverse stock split			13.6-for-1 reverse stock split
Stockholders' equity, stock split, conversion ratio		0.0735
IPO | Common Stock
Nature Of Business [Line Items]
Common stock shares issued and sold	11,302,219
Public offering price per share | $ / shares	$ 18

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Details)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Change in accounting principle, accounting standards update, adopted [true false]	true
Change in accounting principle, accounting standards update, adoption date	Jan. 1, 2021
Change in accounting principle, accounting standards update, immaterial effect [true false]	true
Accounting standards update [Extensible list]	us-gaap:AccountingStandardsUpdate201912Member

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value, Recurring - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	$ 41,043	$ 41,036
Money Market Funds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	41,043	41,036
Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	41,043	41,036
Level 1 | Money Market Funds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total	$ 41,043	$ 41,036

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Fair value assets, level 1 to level 2 transfers amount	$ 0	$ 0
Fair value assets, level 2 to level 1 transfers amount	0	0
Fair value assets, transfers into level 3	0	0
Fair value assets, transfers out of level 3	$ 0	$ 0

Property and Equipment, Net - S

Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 6,774	$ 5,454
Accumulated depreciation	(1,037)	(726)
Property and equipment, net	5,737	4,728
Furniture and Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	40	40
Laboratory Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	6,558	5,247
Computer Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 176	$ 167

Property and Equipment, Net - A

Property and Equipment, Net - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Property Plant And Equipment [Abstract]
Depreciation expense	$ 311	$ 66

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Payables And Accruals [Abstract]
Accrued employee-related and other expenses	$ 1,598	$ 2,727
Accrued research and development	1,669	1,924
Accrued professional fees	997	1,097
Accrued license and milestone fees	80	450
Accrued other	51	62
Total accrued expenses	$ 4,395	$ 6,260

Equity - Additional Information

Equity - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended				3 Months Ended		8 Months Ended	13 Months Ended
	Jan. 31, 2021	Jun. 30, 2020	Feb. 29, 2020	Feb. 28, 2019	Mar. 31, 2021	Mar. 31, 2020	Jan. 31, 2021	Feb. 29, 2020
Class Of Stock [Line Items]
Gross proceeds from stock issued					$ 45,375	$ 17,719
Series A-2
Class Of Stock [Line Items]
Redeemable convertible preferred stock, issued and sold			44,375,000	88,750,000		44,375,000
Redeemable convertible preferred stock, price per share								$ 0.40
Gross proceeds from stock issued								$ 35,600
Series B
Class Of Stock [Line Items]
Redeemable convertible preferred stock, issued and sold	87,259,605	124,519,220			87,259,605
Redeemable convertible preferred stock, price per share							$ 0.52
Gross proceeds from stock issued							$ 110,100

Equity - Summary of Redeemable

Equity - Summary of Redeemable Convertible Preferred Stock (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020	Mar. 31, 2020	Dec. 31, 2019
Temporary Equity [Line Items]
Preferred Stock Authorized		338,973,691
Preferred Stock Issued		251,714,086
Preferred Stock Outstanding		251,714,086
Carrying Value		$ 107,336
Liquidation Value		111,628
Cumulative Undeclared Dividends		$ 7,698
Common Stock Issuable Upon Conversion		18,508,363
Series A-1 Redeemable Convertible Preferred Stock
Temporary Equity [Line Items]
Preferred Stock Authorized	0	20,000,000
Preferred Stock Issued	0	20,000,000
Preferred Stock Outstanding	0	20,000,000	20,000,000	20,000,000
Carrying Value		$ 2	$ 2	$ 2
Liquidation Value		$ 4,000
Common Stock Issuable Upon Conversion		1,470,588
Series A-2 Redeemable Convertible Preferred Stock
Temporary Equity [Line Items]
Preferred Stock Authorized	0	107,194,866
Preferred Stock Issued	0	107,194,866
Preferred Stock Outstanding	0	107,194,866	107,194,866	62,819,866
Carrying Value		$ 42,786	$ 42,786	$ 25,067
Liquidation Value		42,878
Cumulative Undeclared Dividends		$ 5,073
Common Stock Issuable Upon Conversion		7,881,965
Series B Redeemable Convertible Preferred Stock
Temporary Equity [Line Items]
Preferred Stock Authorized	0	211,778,825
Preferred Stock Issued	0	124,519,220
Preferred Stock Outstanding	0	124,519,220
Carrying Value		$ 64,548
Liquidation Value		64,750
Cumulative Undeclared Dividends		$ 2,625
Common Stock Issuable Upon Conversion		9,155,810

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Feb. 05, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted-average grant date fair value of options granted	$ 15.27	$ 1.42
Unrecognized compensation expense related to stock options	$ 13.9
Unrecognized share based compensation expense, recognition period	3 years 1 month 9 days
Number unvested options	359,719
Weighted average exercise price of options exercised and unvested	$ 1.35
Proceeds from unvested options exercises	$ 0.7
Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting rights description	vest over 48 months with 25% vesting after one year followed by ratable monthly vesting over the remaining three years
Vesting period	48 months
Contractual term	10 years
Tranche One | Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	1 year
Vesting percentage	25.00%
Tranche Two | Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	3 years
2021 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares available for future issuance	2,693,301
2015 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares available for future issuance			0

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Weighted-Average Assumptions Used Principally in Determining Fair Value of Options Granted (Details) - Stock Options - $ / shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair value of common stock	$ 22.51	$ 2.18
Expected term (in years)	6 years	5 years 10 months 24 days
Expected volatility	79.70%	75.90%
Risk-free interest rate	0.70%	0.70%
Dividend yield	0.00%	0.00%

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Shares, Outstanding at January 1, 2021	5,084,679
Shares, Granted	394,934
Shares, Exercised	(38,216)
Shares, Outstanding at March 31, 2021	5,441,397	5,084,679
Shares, Exercisable at March 31, 2021	989,860
Weighted-Average Exercise Price, Outstanding at January 1, 2021	$ 3.79
Weighted-Average Exercise Price, Granted	22.51
Weighted-Average Exercise Price, Exercised	1.31
Weighted-Average Exercise Price, Outstanding at Marche 31, 2021	5.16	$ 3.79
Weighted-Average Exercise Price, Exercisable at March 31, 2021	$ 1.80
Weighted-Average Remaining Contractual Term, Outstanding	9 years 2 months 26 days	9 years 5 months 1 day
Weighted-Average Remaining Contractual Term, Exercisable at March 31, 2021	8 years 10 months 6 days
Aggregate Intrinsic Value, Outstanding	$ 206,544	$ 32,086
Aggregate Intrinsic Value, Exercisable at March 31, 2021	$ 40,772

Stock-Based Compensation - Su_3

Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 891	$ 112
Research and Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	449	47
General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 442	$ 65

Leases - Summary of Lease Expen

Leases - Summary of Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Leases [Abstract]
Operating lease cost	$ 747
Short-term lease cost	52	$ 153
Variable lease cost	122	48
Total lease cost	921	$ 201
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows for operating leases	$ 442
Weighted-average remaining lease term (years)	9 years 3 months 29 days
Weighted-average discount rate	9.36%

Leases - Summary of Right-of-Us

Leases - Summary of Right-of-Use Assets and Lease Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Assets
Operating right-of-use assets	$ 16,796	$ 17,117
Liabilities
Operating lease liabilities, current	1,155	863
Operating lease liabilities, non-current	17,121	17,430
Total lease liabilities	$ 18,276	$ 18,293

Net Loss Per Share - Schedule o

Net Loss Per Share - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Numerator:
Net loss	$ (13,723)	$ (7,849)
Cumulative dividends on redeemable convertible preferred stock	(1,228)	(715)
Net loss attributable to common stockholders	$ (14,951)	$ (8,564)
Denominator:
Weighted-average number of common shares outstanding, basic and diluted	22,263,994	145,016
Net loss per share attributable to common stockholders, basic and diluted	$ (0.67)	$ (59.06)

Net Loss Per Share - Potential

Net Loss Per Share - Potential Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Series A-1 Redeemable Convertible Preferred Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potential dilutive securities excluded from computation of diluted net loss per share		20,000,000
Series A-2 Redeemable Convertible Preferred Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potential dilutive securities excluded from computation of diluted net loss per share		107,194,866
Options to Purchase Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potential dilutive securities excluded from computation of diluted net loss per share	5,441,397	1,753,429